TY - JOUR
T1 - Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C
AU - Muñoz-Espinosa, Linda E.
AU - Cordero-Pérez, Paula
AU - Marín-López, Eduardo
AU - Torres-González, Liliana
AU - Malé-Velázquez, Rene
AU - Armienta-Sarabia, Rolando
AU - Hernández-Gómez, María Elena
AU - Núñez-Camarena, José de Jesús Ernesto
AU - Olivera-Martínez, Marco Antonio
AU - Sánchez-Avila, Juan Francisco
N1 - Funding Information:
Declaration of interest: This study was supported by PISA Laboratories, México .
PY - 2013/8
Y1 - 2013/8
N2 - Background and Aims: We undertook this study to evaluate the virological response to and presence of adverse events to natural interferon α (nIFNα; Multiferon®) treatment in previously nonresponsive Mexican patients chronically infected with genotype 1 hepatitis C. Methods: Thirty-nine patients received a 4-week induction of 5 days/week of 6 MU nIFNα plus weight-based ribavirin followed by 3 MU of nIFNα three times a week for 44 weeks. The relationship between viral response and incidence of adverse events was analyzed. Results: Early viral response (EVR) was age- and sex-dependent, with older male patients being less responsive. Sustained viral response (SVR) was evaluated according to: a) intention to treat analysis, b) 48-week treatment and 24-week follow-up (16 patients), and c) patients with EVR (11 patients). None of the factors was significantly different in groups a) and b); however, in group c) there was a better response with a marked viral load decline in younger patients and in patients aged 50 years and older. Five of 39 (13%) patients who completed treatment presented with an SVR. The most common adverse effect was asthenia in 27% of patients. Conclusions: nIFNα could be a useful strategy for re-treatment in chronic hepatitis C, genotype 1, in previously nonresponsive patients. Confirmation of these data in a larger population is required.
AB - Background and Aims: We undertook this study to evaluate the virological response to and presence of adverse events to natural interferon α (nIFNα; Multiferon®) treatment in previously nonresponsive Mexican patients chronically infected with genotype 1 hepatitis C. Methods: Thirty-nine patients received a 4-week induction of 5 days/week of 6 MU nIFNα plus weight-based ribavirin followed by 3 MU of nIFNα three times a week for 44 weeks. The relationship between viral response and incidence of adverse events was analyzed. Results: Early viral response (EVR) was age- and sex-dependent, with older male patients being less responsive. Sustained viral response (SVR) was evaluated according to: a) intention to treat analysis, b) 48-week treatment and 24-week follow-up (16 patients), and c) patients with EVR (11 patients). None of the factors was significantly different in groups a) and b); however, in group c) there was a better response with a marked viral load decline in younger patients and in patients aged 50 years and older. Five of 39 (13%) patients who completed treatment presented with an SVR. The most common adverse effect was asthenia in 27% of patients. Conclusions: nIFNα could be a useful strategy for re-treatment in chronic hepatitis C, genotype 1, in previously nonresponsive patients. Confirmation of these data in a larger population is required.
KW - Adverse events
KW - Hepatitis C virus
KW - Natural interferon alpha
KW - Nonresponders
KW - Sustained viral response
UR - http://www.scopus.com/inward/record.url?scp=84885105897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885105897&partnerID=8YFLogxK
U2 - 10.1016/j.arcmed.2013.08.004
DO - 10.1016/j.arcmed.2013.08.004
M3 - Article
C2 - 24051042
AN - SCOPUS:84885105897
SN - 0188-4409
VL - 44
SP - 444
EP - 448
JO - Archives of Medical Research
JF - Archives of Medical Research
IS - 6
ER -